Disease · MONDO_0100159

pulmonary hypertension, neonatal

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pulmonary hypertension, neonatal. Diseases, record MONDO_0100159. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100159

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pulmonary hypertension, neonatal; Open Targets
Open Targets ID: MONDO_0100159; Open Targets
Other names: persistent pulmonary hypertension in the newborn; Open Targets
NCI Thesaurus: C4732; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SILDENAFIL	CHEMBL192	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ALBUTEROL	CHEMBL714	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALPROSTADIL	CHEMBL495	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OMEGA-3 FATTY ACIDS	CHEMBL4298065		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MILRINONE	CHEMBL189	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
NITROGLYCERIN	CHEMBL730	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GUCY1A1	Soluble guanylate cyclase	2	Soluble guanylate cyclase activator	Unknown	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	2	Soluble guanylate cyclase activator	Unknown	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	2	Soluble guanylate cyclase activator	Unknown	https://conductscience.org/library/genes/2983	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor agonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
MTNR1A	Melatonin receptor	1	Melatonin receptor agonist	Unknown	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	1	Melatonin receptor agonist	Unknown	https://conductscience.org/library/genes/4544	Drugs and targets
PDE3A	cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A	1	Phosphodiesterase 3A inhibitor	Unknown	https://conductscience.org/library/genes/5139	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	1	Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets
PTGER1	Prostaglandin E2 receptor EP1 subtype	1	Prostanoid EP1 receptor agonist	Phase 2	https://conductscience.org/library/genes/5731	Drugs and targets
PTGER2	Prostaglandin E2 receptor EP2 subtype	1	Prostanoid EP2 receptor agonist	Phase 2	https://conductscience.org/library/genes/5732	Drugs and targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01720524	A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn	Phase 3	59	2020-03-25	Pulmonary Hypertension, Familial Persistent, of the Newborn	SILDENAFIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT06603766	Treatment of Persistent Pulmonary Hypertension in Neonates With Nebulized Magnesium Sulfate	Phase 2/3	40	2025-02-05	Magnesium Sulfate - PPHN	MAGNESIUM SULFATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01088997	Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn	Not applicable	12	2016-07-12	Persistent Fetal Circulation Syndrome	MILRINONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01069861	Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)	Phase 2	4	2012-12-03	PPHN, Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure	SILDENAFIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05527704	the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)	Phase 3	608		TTN, Respiratory Failure, PPHN	ALBUTEROL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00139217	NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn	Not applicable	400		Pulmonary Hypertension	NITRIC OXIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05741229	The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns	Not applicable	80		Persistent Pulmonary Hypertension of the Newborn, Echocardiography, Respiratory Disease	NITROGLYCERIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT07090720	Melatonin Effects on the Left Ventricular Function in Neonates With Persistent Pulmonary Hypertension	Not applicable	80		Melatonin, Left Ventricular Function, Neonates, Persistent Pulmonary Hypertension	MELATONIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04031508	Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH	Phase 2	40		Pulmonary Hypertension of Newborn, Diaphragm Defect	OMEGA-3 FATTY ACIDS	Open Targets' reading of its record	ClinicalTrials.gov
NCT04328636	Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn	Phase 1/2	28		Persistent Fetal Circulation, Persistent Pulmonary Hypertension of the Newborn, PPHN	MAGNESIUM SULFATE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IV Sildenafil vs Placebo: Number of Participants With Laboratory Abnormalities	27 of 29	22 of 28	57	NCT01720524	Trial comparisons
Nebulized Magnesium (NebMag) Group 1 vs Intravenous Magnesium (IVMag) Group 2: deaths from any cause	0 of 20	0 of 20	40	NCT06603766	Trial comparisons
Nebulized Magnesium (NebMag) Group 1 vs Intravenous Magnesium (IVMag) Group 2: serious adverse events	0 of 20	0 of 20	40	NCT06603766	Trial comparisons
High Dose Milrinone vs Low Dose Milrinone: serious adverse events	0 of 7	0 of 5	12	NCT01088997	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41954764	DERIVED	1	PubMed
40888971	DERIVED	1	PubMed
36714639	DERIVED	1	PubMed
34052232	DERIVED	1	PubMed
33415555	DERIVED	1	PubMed
25496504	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100159

GET https://conductscience.org/api/diseases/v1/MONDO_0100159/drugs

API reference For AI assistants